Csl Behring
Clinical trials sponsored by Csl Behring, explained in plain language.
Makes plasma-derived and recombinant therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Hope dashed: drug trial for Post-COVID racing heart stopped early
Disease control TerminatedThis study tested a drug called IgPro20 (HIZENTRA) to see if it could help people with post-COVID POTS, a condition that causes a rapid heart rate and dizziness when standing. The trial was stopped early after enrolling only 16 adults. The goal was to see if the drug could reduce…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Hizentra shows promise for rare muscle and skin disease
Disease control TerminatedThis study tested a medicine called Hizentra (IgPro20) in 134 adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. The goal was to see if weekly shots under the skin could improve symptoms better than a placebo. The study was stopped early, but res…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Blood-Clotting drug trial for trauma bleeding halted early
Disease control TerminatedThis study tested a single dose of a drug called BE1116 (a 4-factor prothrombin complex concentrate) in people with traumatic injuries and severe bleeding. The goal was to see if it could improve survival within 6 hours compared to a placebo. The trial was stopped early after enr…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC